Search results
Results from the WOW.Com Content Network
When actinic granuloma-like lesions appear in non-exposed areas, the rash is known as annular elastolytic giant cell granuloma. Though these can be easily distinguished based on histopathologic features and laboratory findings, the differential diagnosis includes tinea corporis , sarcoidosis , subacute lupus erythematosus , granuloma annulare ...
Granuloma annulare (GA) is a rare, [1] sometimes chronic skin condition which presents as reddish bumps on the skin arranged in a circle or ring. [2] It can initially occur at any age, though two-thirds of patients are under 30 years old, and it is seen most often in children and young adults.
Annular elastolytic giant-cell granuloma (also known as "Giant cell elastophagocytosis," [1] "Meischer's granuloma," [2] "Miescher's granuloma of the face" [1]) is a cutaneous condition characterized histologically by a dermal infiltrate of macrophages.
Actinic granuloma; Annular elastolytic giant-cell granuloma; B. Benign cephalic histiocytosis; ... Generalized granuloma annulare; Giant cell elastophagocytosis;
Actinic keratosis treatments. Treatment may include liquid nitrogen, scraping, chemical peels or other therapies to remove the actinic keratosis. Read more about actinic keratosis and how to treat it.
Generalized granuloma annulare is a chronic granulomatous dermatosis that typically affects young adults' distal extremities and manifests as annular grouped papules. [2] On the trunk and extremities, numerous flesh-colored papules arranged in an annular pattern are the hallmark of generalized granuloma annulare. These lesions are frequently ...
692.75 Disseminated actinic porokeratosis; 692.8 Contact dermatitis and other eczema due to other specified agents. 692.81 Dermatitis, due to cosmetics; 692.83 Dermatitis, due to metals; 692.9 Contact dermatitis NOS; 693 Dermatitis due to substances taken internally. 693.0 Dermatitis due to drugs and medicines taken internally; 693.1 Dermatitis ...
Scientists have discovered that inhibiting a protein could stop dyskinesia symptoms and erase the brain's "bad memory" response to long-term Parkinson's therapies.